Abnova (Taiwan) Corporation
Research Abnova (Taiwan) Corporation (4133.TW) on Bullrun: market cap TWD 1.28B, P/E 28.6, dividend yield 0.5%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4133.TW
- ExchangeTW
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 1.28B
- P/E28.6
- Dividend yield0.5%
- Financial periodQ2 2026
- RevenueTWD 88.33M
- Net incomeTWD 6.18M
- Free cash flowTWD 10.06M
- Gross margin51.3%
Valuation Snapshot
latest market cap is TWD 1.28B; P/E is 28.6; dividend yield is 0.5%.
Peer valuation comparison
Latest P/E is 28.58x versus a Healthcare sector median of 21.74x (31.4% above).
Latest dividend yield is 0.53% versus a Healthcare sector median of 2.4% (77.9% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 1.28B | 28.6 | 0.5% | 0.11 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.11 TWD, yield 0.5%.
About Abnova (Taiwan) Corporation
Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company's products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Abnova (Taiwan) Corporation's market cap?
Abnova (Taiwan) Corporation's market capitalization is TWD 1.28B.
What is Abnova (Taiwan) Corporation's P/E ratio?
Abnova (Taiwan) Corporation's price-to-earnings (P/E) ratio is 28.6.
Does Abnova (Taiwan) Corporation pay a dividend?
Abnova (Taiwan) Corporation has a dividend yield of 0.5%.
What does Abnova (Taiwan) Corporation do?
Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company's products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, Nano, DNAxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies.